Scholarlink

Background <p>Calcitonin Gene-Related Peptide targeting monoclonal antibodies (CGRP mAbs) were introduced for migraine prophylaxis in Sweden through the National Joint Introduction process to ensure an equal, cost-effective, and appropriate national use. This study aimed to assess prescriber adherence to treatment guidelines and evaluate patient treatment persistence during the national introduction of CGRP mAbs.</p> Methods <p>In this register-based cohort study, we followed individuals with a migraine diagnosis or dispensation of migraine drugs within Stockholm County from July 2018 to June 2022. We evaluated the guidelines for CGRP mAb treatment (erenumab, fremanezumab, or galcanezumab) according to four categories: 1) patient eligibility, 2) prescriber qualifications, 3) treatment evaluation, and 4) monitoring/reporting. We used a Sankey diagram to illustrate treatment switching and discontinuation patterns and employed boxplots along with Kaplan-Meier estimates to assess the persistence to CGRP mAbs.</p> Results <p>Among 93,263 eligible individuals, 2266 (2%) had at least one CGRP mAb dispensation. Most (90%) had a prior migraine diagnosis at the first CGRP mAb dispensation, and 66% had been dispensed at least two prior prophylactic drugs against migraine. In nearly all cases (97%), CGRP mAb prescriptions were issued by neurology or headache specialists. Switching between CGRP mAbs was common and treatment persistence declined across successive sequences. Overall median treatment duration was 5.8 months (interquartile range: 2.8–11.9 months) and was longer for erenumab than fremanezumab and galcanezumab in sequence 1, but not in sequence 2. Kaplan–Meier analysis revealed a 12-month persistence of 58% in sequence 1, 53% in sequence 2, and 46% in sequence 3. A higher persistence was observed for fremanezumab and galcanezumab compared with erenumab in sequence 1, while estimates were similar in sequence 2.</p> Conclusion <p>Prescribers within Stockholm County adhere well to CGRP mAb treatment guidelines, with dispensations largely supported by a sound medical rationale, indicating appropriate integration into clinical practice. Guidance on switching between CGRP mAbs is limited and our findings show frequent switching and reduced persistence across sequences. These insights can help clinicians avoid unnecessary switches and optimize migraine care and resource use.</p> Graphical abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Prescriber adherence to treatment guidelines for monoclonal antibodies against Calcitonin Gene-Related Peptide in migraine prophylaxis – a register-based cohort study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月10日

查看全文
  • Sofia Nordenmalm,
  • Rickard E. Malmström,
  • Sara Freyland,
  • A. Ingela M Nilsson Remahl,
  • Karin Wirdefeldt,
  • Isabella Ekheden

摘要

Background

Calcitonin Gene-Related Peptide targeting monoclonal antibodies (CGRP mAbs) were introduced for migraine prophylaxis in Sweden through the National Joint Introduction process to ensure an equal, cost-effective, and appropriate national use. This study aimed to assess prescriber adherence to treatment guidelines and evaluate patient treatment persistence during the national introduction of CGRP mAbs.

Methods

In this register-based cohort study, we followed individuals with a migraine diagnosis or dispensation of migraine drugs within Stockholm County from July 2018 to June 2022. We evaluated the guidelines for CGRP mAb treatment (erenumab, fremanezumab, or galcanezumab) according to four categories: 1) patient eligibility, 2) prescriber qualifications, 3) treatment evaluation, and 4) monitoring/reporting. We used a Sankey diagram to illustrate treatment switching and discontinuation patterns and employed boxplots along with Kaplan-Meier estimates to assess the persistence to CGRP mAbs.

Results

Among 93,263 eligible individuals, 2266 (2%) had at least one CGRP mAb dispensation. Most (90%) had a prior migraine diagnosis at the first CGRP mAb dispensation, and 66% had been dispensed at least two prior prophylactic drugs against migraine. In nearly all cases (97%), CGRP mAb prescriptions were issued by neurology or headache specialists. Switching between CGRP mAbs was common and treatment persistence declined across successive sequences. Overall median treatment duration was 5.8 months (interquartile range: 2.8–11.9 months) and was longer for erenumab than fremanezumab and galcanezumab in sequence 1, but not in sequence 2. Kaplan–Meier analysis revealed a 12-month persistence of 58% in sequence 1, 53% in sequence 2, and 46% in sequence 3. A higher persistence was observed for fremanezumab and galcanezumab compared with erenumab in sequence 1, while estimates were similar in sequence 2.

Conclusion

Prescribers within Stockholm County adhere well to CGRP mAb treatment guidelines, with dispensations largely supported by a sound medical rationale, indicating appropriate integration into clinical practice. Guidance on switching between CGRP mAbs is limited and our findings show frequent switching and reduced persistence across sequences. These insights can help clinicians avoid unnecessary switches and optimize migraine care and resource use.

Graphical abstract